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Abstract 
It has been recently suggested that Japanese herbal (kampo) medicines, such as 
Kami-Untan-To, may improve cognitive function in elderly  subjects with  Alzheimer's 
disease. Polygalae Radix is thought to be a useful component ofKami-Untan-To 
because itenhances the activity of choline acetyltransferase in cultured neuronal cells. 
The purpose of the present study was to investigate he safety and usefulness of Kihito 
Extract Granules, acommercially available Japanese herbal medicine that contains 
Polygalae Radix, for elderly patients with senile dementia. Seventy-five elderly subjects 
 (84.4  -±6.4years) with senile dementia ofAlzheimer type according to DSM-IV criteria 
were randomly assigned to the Nontreatment, Goshajinkigan (control kampo medicine), 
or Kihito groups. Each medicine was given three times a day for 3 months. There was 
no severe adverse vent in all groups. We examined the Mini Mental State Examination 
(MMSE), the activities of daily living (ADL) scale, and cerebrovascular single photon 
emission computed tomography (SPECT) before and after treatment. MMSE scores 
were significantly improved only in the Kihito group  (+1.65-10.53) but not in the 
Nontreatment  (-0.3  ±  0.67) and Goshajinkigan  (-0.58  ±  0.49) groups. ADL scores 
remained unchanged inall groups. Treatment with Kihito was not associated with an 
increase in CBF. These results propose that Kihito may be useful and has a potential to 
be tested as a medicine for Alzheimer-type s nile dementia, lthough further 
examination is required to clarify the mechanism ofthe improving effect of Kihito on 
cognitive function. 
Key words: cognitive function, dementia, herbal medicine, Goshajinkigan, Kihito 
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Introduction 
Alzheimer-type d mentia sa common form of dementia nthe elderly
, and the 
morbidity of Alzheimer's disease has been increasing inJapan. Previous reports have 
shown a loss of  acetylcholine (Ach) in the brains of patients with Alzheimer's di
sease, a
decrease inthe activity of choline acetyltransferase (ChAT), the enzyme that 
biometabolizes Ach, and loss of presynaptic cholinergic neurons in the basal  nucleus'-'l 
                                                            Because itis likely that he loss of central cholinergic activity is associatedwith 
cognitive worsening in patients with Alzheimer-type d mentia, it has been hypothesized 
that cholinergic augmentation could improve the cognitive ability of these patients. 
Recently, clinical trials with  donepezi15-7, revastigmine8, and galanthamine9 have 
demonstrated that cholinesterase inhibitors, which inhibit breakdown of  acetylcholine 
and increase its availability to synapses, how overall beneficial effects in cognitive 
function in patients with Alzheimer's disease. 
      There are many reports thatherbal medicines may be useful for dementia n
animal models and  humans1°-12. Some of these reports demonstrate the effect of herbal 
medicines on metabolism ofAch. It was reported, for example, that a single preparation 
of Polygalae Radix, an herbal medicine, considerably enhanced ChAT activity in 
cultured rat septal neurons  13. Furthermore, it was reported that Japanese herbal (kampo) 
medicines such as Kami-Untan-To (KUT) , a cocktail of herbal medicines containing 
Polygalae Radix, increased Ach synthesis through enhancement of ChAT  activity14-16 
and that KUT prevented the progression fdementia nAlzheimer's  disease7  . Of 
importance, the omission of Polygalae Radix from the basal cocktail of KUT 
dramatically reduced ChAT activity  13. However, KUT is not commercially available in 
Japan. Kihito is a kampo medicine containing Polygalae Radix that is commercially 
available in Japan for persons of frail constitution with anemia, anxiety, palpitation, and  
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isomnia  17. The purpose of the present study was to evaluate the efficacy and safety of 
Kihito in the clinical context for patients with mild to moderate Alzheimer-type 
dementia. 
Methods 
Study subjects 
      A total of 75 elderly subjects with senile dementia of Alzheimer type were 
recruited from patients who were admitted and had undergone medical investigation at 
Hanwa Daini Senboku Hospital, Japan. Senile dementia ofAlzheimer type was 
diagnosed based on the criteria of the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition  (DSM-IV, American Psychiatric Association, Washington D.C., 
1994)  18. All subjects showed a Hachinski  ischemic score of 4 points or less. Patients 
had Mini Mental State Examination (MMSE) scores ranging between 10 and 26 at the 
time of initial imaging. We also excluded patients with following diseases in
uncontrolled and severe status; hypertension (systolic blood pressure  >160mmHg, 
diastolic blood  pressure  >100mmHg), diabetes mellitus  (HbAlc  > 8.0%), dyslipidemia 
(total  cholesterol  >260mg/dl), cardiovascular diseases (NYHA III or  IV, peripheral 
artery disease with class III or IV of Fontaine classification), renal failure (serum 
 creatinine  >2.0mg/d1), and a mental disorder such as depression. We also excluded 
patients with prominent cerebral infarction diagnosed by magnetic resonance imaging. 
None of the assigned patients received cholinesterase inhibitors. 
Study drugs 
     We used Goshajinkigan Extract Granules for Ethical Use (TUMURA & Co. 
Tokyo, Japan,  7.5g/day) and Kihito Extract Granules for Ethical Use (TUMURA & Co. 
Tokyo, Japan, 7.5g/day). For 7.5 g of Goshajinkigan (GJG), there are 4.5 g of extract of 
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following dried medical herbs; Moutan Cortex (3.0 g),  Corni Fructus (3.0 g), 
Dioscoreae Rhizoma (3.0 g), Rehmanniae Radix (5.0 g), Cinnammoni Cortex (1.0 g), 
Aconiti Tuber (1.0 g), Achyranthis rRadix (3.0 g), Alismatis Rhizoma (3.0 g), 
Plantaginis Semen (3.0 g), and Poria (3.0 g). For 7.5 g of Kihito Extract Granules, there 
are 4.5 g of extract of following dried medical herbs; Angelicae Radix (2.0 g), Longan 
Arillus (3.0 g), Polygalae Radix (2.0 g), Saussureae Radix (1.0 g), Zizyphi Spinosi 
Semen (3.0 g), Astragali Radix (3.0 g), Atractylodis Rhizoma (3.0 g), Ginseng Radix 
(3.0 g), Glycyrrhizae Radix (1.0 g), Zingiberis Rhizoma (1.0 g), Zizyphi Fructus (2.0 g), 
and Poria (3.0 g). We chose GJG as a control for Kihito because GJG contains extracts 
of herbs that are completely different from Kihito, except Poria. Throughout the study, 
all subjects were hospitalized tocheck compliance. During the trial, no other major new 
medication was allowed. 
Study protocol 
      Subjects were randomly assigned to one of three groups: the Nontreatment 
group, the Goshajinkigan group (GJG group), or the Kihito group. Patients assigned to 
the GJG and Kihito groups received GJG  (7.5g/day) and Kihito  (7.5g/day), respectively, 
after meals three times a day for 3 months. 
      MMSE scores and activities of daily living (ADL) scores were assessed atthe 
beginning of the trial and after 3 months of medication. The evaluation of MMSE and 
ADL were performed with single blind method. Single photon emission computed 
tomography (SPECT) was performed at the beginning of the trial and after 3 months of 
medication i 10 patients to evaluate changes in cerebral blood flow (CBF). SPECT was 
performed using the model Toshiba E-Cam in 6 patients from the GJG group and 4 
patients from the Kihito group with  99mTechnesium-ethyl cysteinate dimer  (99mTc-ECD). 
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   Mean CBF (mCBF) was analyzed by Patlak plot analysis with the reference inthe aortic 
   arch; then, regional CBF (rCBF) was estimated by applying Lassen's correction 
    algorithm  19 and three-dimensional stereotaxic  ROI template (3D-SRT)20 to objectively 
    measure rCBF. The rCBF was calculated inthe anterior cingulated, posterior cingulated, 
    frontal, parietal, temporal, occipital, and hippocampus segments. Increased cases of 
   CBF were determined byan increase in at least one rCBF measurement of morethan 
    15% compared to the basal evel. We set cutoff point at 15% based on the following 
   information; (1) The data of reproducibility provided by the manufacturer indicated that 
   inter-measurement variability of rCBF is between 5-10% using Patlak plot analysiswith 
   3D-SRT, (2) Original  article20 of3D-SRT showed that CBF values after treatmentwith 
   placebo distributed within 15% changes ofCBF values before treatment in 95% of
    352-pair examinations. 
         The study protocol was approved by the ethical committee ofHanwa Daini 
   Senboku Hospital, and all subjects and/or their families gave written informed consent 
   to participate inthe study. All procedures followed were in accordance with the
   provisions of the Declaration of Helsinki n 1995. 
   Statistical analysis 
          Statistical nalysis was performed using StatView (Abacus Concepts Inc., 
   Berkeley, CA). Effects of treatment on each parameter were analyzed by analysis of 
   variance (ANOVA), followed by Fisher's protected least significant difference t st. 
   Effects of treatment for three months on changes in MMSE scores were assessed by 
   paired t-tests. Interaction between the effects of treatment and changes in MMSE scores 
   were analyzed ANOVA with repeated measurement. Prevalence ofhypertensiona d 
   diabetes mellitus among the three groups was analyzed by chi-square t st. Comparisons 
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of changes in MMSE and semi-quantitatively measured CBF with SPECT between the 
GJG and Kihito groups were performed with chi-square t sts. A value of P < 0.05 was 
considered statistically significant. 
Results 
Study safety 
      We performed statistical nalysis in 64 patients except withdrawal cases. The 
subjects numbers used in the analysis were 20 for the Nontreatment group, 24 for the 
GJG group, and 20 for the Kihito group. Characteristics of these patients are presented 
in Table 1. 
     Eleven subjects withdrew before the end of study because of withdrawal of 
consent within a month (GJG 3 subjects, Kihito 3 subjects), transfer to other hospital for 
non-medical reasons (GJG 1 subject,  Kihitol subject), worsening  of  ADL by accidental 
fracture (Kihito 1 subject), or possible adverse ffects  (GJG 1 subject (diarrhea), Kihito 
1 subject (hypertension)). The major eason of withdrawal of consent was due to bitter 
taste of the medicine. In patients possibly suffered adverse vents, the complaints 
disappeared after discontinuation f the assigned rug. All laboratory findings, 
including liver  function, were within normal range during the oral administration f 
GJG and Kihito. There was no severe adverse vent in all groups. There was no 
significant difference between the GJG and Kihito groups in terms of the overall safety 
rating (Table2). 
Effect of treatment on MMSE, ADL, and CBF 
      There was no significant differenceinbaseline characteristics among the three 
treatment groups (Table 1). 
 -  7  -
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       MMSE scores howed significant improvement at 3 months after treatment in 
the Kihito group, but not in the Nontreatment or GJG groups (Fig. 1). MMSE scores at 
3 months after treatment compared topretreatment scores also showed an increase by 
treatment only in the Kihito group (Fig.2). Improvement of mental state in the Kihito 
group was most manifested as changes in orientation and attention compared with those 
in memory and language (Fig.3). 
      Basal evels of ADL did not differ among the three groups (Table 1), and ADL 
was unchanged atthree months after treatment in all groups. 
      Treatment with Kihito was not associated with an increase in CBF. Regarding 
the increased area of CBF, it was increased mainly in frontal and cingulate in both GJG 
and Kihito groups. However, we could not perform comparison of increased area 
between the GJG and Kihito groups because the number of subjects with increased 
rCBF was less for statistical nalysis. 
Discussion 
      The present study demonstrated hat Kihito treatment significantly improved 
cognitive function as estimated by MMSE, especially for scores in orientation and 
attention, compared with nontreatment and GJG treatment in patients with 
Alzheimer-type d mentia. Differences in MMSE scores between before and after 
treatment in our Kihito group were about 2 points, which was similar to improvements 
reported previously in studies assessing the effect of herbal medicine on cognitive 
function7'21. Previous reports using donepezil demonstrated a similar or lesser extent of 
                                                                                     •.
022- improvement in MMSE compared with our study using Kinn24. An increase of 
MMSE scores in the Kihito group in contrast to a decrease or no change in other 
treatment groups suggests the possibility of usefulness of Kihito for patients with  
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Alzheimer-type dementia. 
      We chose Kihito because it contains Polygalae Radix, is commercially 
available in Japan, and has been widely used for the elderly. Kihito is generally 
prescribed in Japan for persons of frail constitution with anemia, anxiety, palpitation, 
and insomnia17. We chose GJG as the control medicine in addition to a nontreatment 
group because: (1) GJG does not contain Polygalae Radix and other components of GJG 
have not been reported to affect cognitive function; (2) in comparison with non-herbal 
medicines, GJG and Kihito are similar in taste, color, and shape; and (3) both Kihito and 
GJG are frequently prescribed for elderly people. GJG has been prescribed in Japan for 
elderly people suffering from lumbago, back pain, and oliguria. Kihito and GJG have 
only one ingredient, Poria, in common. However, Poria demonstrates differential 
phaimacologic action in each combination because of interaction with the different 
components in each medicine. 
      The mechanism by which Kihito improves cognitive function may be related to 
the elevation of Ach levels by activation of ChAT, primarily attributable to Polygalae 
radix, as previously shown in cultured rat septal neurons  13. This hypothesis is supported 
by the preventive ffect of KUT, a cocktail of herbal medicines containing Polygalae 
Radix, on the progression of dementia in Alzheimer's  disease7 and by reduction of 
ChAT activity when Polygalae Radix is omitted from  KUT13. The mechanism of 
activation of ChAT activity is reported to be caused by transcriptional ctivation of 
ChAT  mRNA  25'26. On the other hand, donepezil increases Ach levels in the brain via 
inhibition of Ach degradation by acetylcholine sterase  27-29.  Furthermore, KUT 
increases nerve growth factor mRNA in cerebral cortex cells25. Therefore, Polygalae 
Radix in Kihito may affect cognitive function via multiple pathways. 
      Another possible mechanism by which Kihito improves cognitive function is  
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an effect on CBF. In previous tudies, both Nakano et  a130 and Nobili et  a131 reported that 
rCBF in critical areas was maintained but not improved after  long-teem treatment (12 
months) and the MMSE score declined significantly both in untreated and in treated 
group with donepezil. Those reports are consistent with the report of Rogers et al32 that 
cognitive improvements gained early with Ch-E inhibitors gradually fade away after 
several months of treatment. On the other hands, Carvolo et  a133 and Mega et  a134 
reported that MMSE score was significantly improved and improvement i  the rCBF 
pattern correlated with cognitive improvement with Ch-E inhibitors after short-term 
treatment (3-4 months). The present study, short-term treatment, demonstrated that 
improvement of CBF by Kihito was not superior to that elicited by  GJG. This result may 
be interpreted by several possible causes. The first possibility is that our evaluation 
system was less sensitive to detect quantitatively changes in rCBF compared with the 
previously reported methods such as the statistical parametric mapping programs and 
three-dimensional stereotaxic surface  projections33'35. The second possibility is that role 
of an increase of CBF in the improvement i  MMSE by Kihito is small compared with 
activation of ChAT or other unknown pathways. The third possibility is that GJG treated 
group was inappropriate ascontrol because GJG per se is known to increase peripheral 
vascular  flovv36. Further studies are required to clarify the precise mechanism. 
      The present study demonstrated improvement of mentalstate, especially in
orientation and attention, inthe Kihito group. Ushijima et al.37 reported an association 
between rCBF and MMSE scores in patients with Alzheimer's disease. They 
demonstrated a relationship between a decline in rCBF in the parietal cortex and 
hippocampus and disorientation. I  addition, there was a decrease inrCBF in the 
anterior temporal cortex associated with registration; i  the frontal cortex associated 
with attention and calculation; inthe medial temporal cortex associated with recall; and  
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in the posterior temporal cortex associated with language. As described above, 
donepezil increases rCBF, including in the prefrontal cortex. These reports are 
consistent with the previous report of a multicenter, andomized, controlled trial that 
donepezil-treated patients howed improvements in tests of attention and psychomotor 
speed  38. We need further study to clarify whether Kihito might improve attention and 
orientation by any specific regional increases in CBF. 
      There are several study limitations in ourstudy to conclude the effect of Kihito 
on MMSE including its precise mechanism. We evaluated MMSE and ADL with single 
blind method. Although MMSE consists of simple questions and inter-observer 
reliability is high39, double blind evaluation would be more reliable. Another study 
limitation is that the number of subjects who were  performed SPECT was too small to 
conclude the relation between changes in CBF and changes in MMSE. Further studies 
are required to clarify the role of Kihito on regional changes in CBF and the relation 
between changes in MMSE and rCBF by Kihito. Taking these limitations into 
consideration, we  concludethat Kihito would be a safe and probably effective herbal 
medicine for symptomatic treatment in Alzheimer-type dementia nd has opened the 
window to investigations of its usefulness in a larger-scale trial. 
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Table 1. Patient characteristics 
                    Nontreatment GJG Kihito Statistics 
Number 20 24 20 
Age, years  82.8+8.1  84.2+6.4  86.1+5.0 N.S 
Male/Female 4/16 2/22 5/15 N.S 
Education, years  9.0+0.5  8.6+0.5  8.8+0.5 N.S 
Hypertension, % 55.0 37.5 35.0 N.S 
Diabetes mellitus, % 5.0 12.5 25.0 N.S 
Hachinski ischemic score  2.3+1.5  2.7+1.3  2.1+1.0 N.S 
MMSE score  17.6+5.0  18.1+4.2  17.6+4.1 N.S 
ADL score (Barthel index)  9.5+5.3  12.4+5.9  12.5+5.9 N.S 
Serum albumin, g/dl  3.48+0.37  3.57+0.32  3.48+0.33 N.S 
Serum creatinine,  mg/dl  0.88+0.53  0.91+0.57  0.85+0.39 N.S 
Hemoglobin,  mg/dl  10.82+1.68  11.11+1.37  10.88+1.42 N.S 
 GJG, Goshajinkigan; MMSE, mini mental state xamination; ADL, activity of daily life. 
N.S; not significant. Values are  mean+SD.  
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Table 2. Comparison of blood biochemical analysis among the three groups.
Nontreatment GJG Kihito
3 3 3
Pre Pre Pre
months months months
Serum albumin, 3.48± 3.50± 3.57±  3.57  ± 3.48± 3.54±
g/dl  0.37 0.37 0.32 0.34  0.33 0.33
Serum creatinine,  0.88±  0.85±  0.91±  0.91± 0.85± 0.84±
 mg/dl 0.53 0.49 0.57 0.63 0.39 0.32
Hemoglobin, 10.82 ± 10.84±  11.11  ±  11.02±  10.88± 11.37±
 mg/d1 1.68 1.96 1.37 1.38 1.42 1.34
Serum
AST(asparatate 21.80±  23.20  ±  24.16±  23.58  ±  19.20±  18.75  ±
aminotransferase), 10.52 14.02 14.92 13.09 5.05 5.81
 IU/1
Serum
ALT(alanine 14.85±  16.45  ± 18.75 ±  17.91  ± 12.40 ±  11.65±
aminotransferase), 10.88 14.94 16.35 12.78 5.52  7.30
 IU/1
GJG, Goshajinkigan; Values are mean±SD. There was no statistically significant
difference among the three groups in blood biochemical analysis.
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Figure 1. Comparison of MMSE scores before and 3 months after 
treatment in three groups. MMSE was performed at the beginning of the trial 
and after 3 months of medication. Data are given as mean ± SEM. ANOVA 
with repeated measurement showed that F value of interaction between the 
effects of treatment and changes in MMSE scores were 4.55  (P=0.015). 
Significant improvement of MMSE was observed only in the Kihito group  (*: 
 P<0.01 pretreatment vs. 3 months of treatment by paired t-test).
-  14  -
Higashi et aL Usefulness of Kihito on cognitive function 15
Changes in MMSE score
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 Figure 2. Comparison of differences of MMSE scores between before and after 
treatment among three groups. P values from post hoc analysis for multiple 
comparisons between two groups are shown in the figures. Data are given as mean ± 
SEM.
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Figure 3. Comparison of differences of MMSE scores between before and after treatment 
among three groups: Subanalysis of four categories of mental states. Questions of MMSE 
were categorized into four mental  states;4° orientation (10 points), memory (registration and recall, 
6 points), attention (attention and calculation, 5 points), and language (9 points). Data are given as 
mean ± SEM of average scores.
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